Page 9 - CIRN-AR-2015-PRESS.indd
P. 9
CIRN NETWORKS
Special Immunization
Clinics (SIC) Network
The SIC network enrolls patients with prior adverse events following
immunization (AEFI) and has built a national patient registry to gather
data on the types of AEFI assessed in the clinics and patient outcomes
after revaccination. The SIC Network has sites in 6 Provinces across
Canada: Nova Scotia, Quebec, Ontario, Saskatchewan, Alberta, and British
Columbia.
The SIC network is designed to address the following
main questions:
• Among patients referred to the SIC following an
AEFI, what is the risk of recurrence of the AEFI upon
re-immunization?
• Among children with primary immunodefi ciency,
what is the risk of medically-attended AEFI and how
complete are their immunizations?
• Among children with acute lymphocytic leukemia,
what factors predict low vaccine titres at the end
of chemotherapy? What factors predict robust
responses to pneumococcal and tetanus booster
immunization?
As of January 2015, 142 patients were were referred to
the SIC Network for prior AEFI or an underlying condition
that complicated vaccination. Of these, 101 were
assessed and 89 were enrolled. To date, 44/58 (76%)
patients offered revaccination have been immunized and
followed up. Nine patients (20%) experienced adverse
events; none were serious (resulted in hospitalization
>24 hours, permanent disability or death).
This year, the SIC network plans to start two new
projects; the fi rst will study childhood immunization
practices among children with primary immune
defi ciencies, and the second will measure the
immunogenicity and safety of immunization in
children who have completed chemotherapy for acute
lymphoblastic leukemia.
2015 ANNUAL REPORT 7
Special Immunization
Clinics (SIC) Network
The SIC network enrolls patients with prior adverse events following
immunization (AEFI) and has built a national patient registry to gather
data on the types of AEFI assessed in the clinics and patient outcomes
after revaccination. The SIC Network has sites in 6 Provinces across
Canada: Nova Scotia, Quebec, Ontario, Saskatchewan, Alberta, and British
Columbia.
The SIC network is designed to address the following
main questions:
• Among patients referred to the SIC following an
AEFI, what is the risk of recurrence of the AEFI upon
re-immunization?
• Among children with primary immunodefi ciency,
what is the risk of medically-attended AEFI and how
complete are their immunizations?
• Among children with acute lymphocytic leukemia,
what factors predict low vaccine titres at the end
of chemotherapy? What factors predict robust
responses to pneumococcal and tetanus booster
immunization?
As of January 2015, 142 patients were were referred to
the SIC Network for prior AEFI or an underlying condition
that complicated vaccination. Of these, 101 were
assessed and 89 were enrolled. To date, 44/58 (76%)
patients offered revaccination have been immunized and
followed up. Nine patients (20%) experienced adverse
events; none were serious (resulted in hospitalization
>24 hours, permanent disability or death).
This year, the SIC network plans to start two new
projects; the fi rst will study childhood immunization
practices among children with primary immune
defi ciencies, and the second will measure the
immunogenicity and safety of immunization in
children who have completed chemotherapy for acute
lymphoblastic leukemia.
2015 ANNUAL REPORT 7
